Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company currently commercializes three travel vaccines, including a single-shot chikungunya vaccine, and distributes certain third-party vaccines. Its pipeline includes the only Lyme disease vaccine candidate in advanced clinical development, developed in partnership with Pfizer, and the most advanced Shigella vaccine candidate in clinical trials. Valneva utilizes expertise in various vaccination modes to create vaccines for diseases where no current solutions exist or where existing options can be improved.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage valneva.com
Sector Healthcare IR page valneva.com/investors
Tags
vaccines, infectious diseases, chikungunya, lyme disease, shigella, travel vaccines, prophylactic vaccines, IXIARO, JESPECT, DUKORAL, IXCHIQ, EB66, IC31
Press page valneva.com/media/press-releases

Metrics

Valuation  
Market cap € 744.97M
Market cap (USD) $ 818.648M
P/E -4.89
PEG —
P/BV 9.18
P/S 5.21
P/OCF -14.08
P/FCF -13.00
Dividend yield —
Turnover / mcap —
Returns  
ROE -80.2%
ROI -40.4%
ROIC -21.6%
Profit margin -66.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 226.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2015 FY 2014 FY 2013
Revenue 174.659M 169.579M 153.713M 361.303M 348.086M 110.321M 126.196M 78.36M 36.922M 30.445M
Net profit -115.192M -12.247M -101.429M -143.279M -73.425M -64.393M -1.744M -20.617M -26.272M -24.11M
Free cash flow -57.314M -81.083M -216.975M -274.589M -15.328M 118.802M — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2015 FY 2014 FY 2013
Share price 4.24 2.66 5.65 7.06 18.26 — — — — —
Price performance 12m 0.59 -0.53 -0.2 -0.61 — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) — 19.2M 44M 23.9M 41.6M 35.2M 27.8M
↳ YoY growth +128.9% -45.7% +74.2% -15.5% -21.0%
↳ 5y CAGR +7.7%
Borrowings, current (EUR) — 6.99M 7.11M 11.6M 44.1M 20.9M 17.9M
Borrowings, non-current (EUR) — 46.4M 50.7M 87.2M 133M 167M 161M
Lease liabilities (EUR) — 52.1M 56.8M 53.6M 32M 28.9M 28.1M
Cash and deposits (EUR) 77.1M 64.4M 204M 287M 126M 168M 110M
Intangible assets (EUR) — 35.4M 32.7M 28.7M 25.6M 25.3M 22.3M
Right-of-use assets (EUR) — 43.4M 48.3M 41.6M 20.4M 19.2M 18.6M
Net debt (borrowings + leases - cash) (EUR) — 41M -89.7M -134M 82.7M 48M 97.6M
Cash flow detail
Operating cash flow (EUR) 5.53M 138M 76.9M -245M -203M -67.2M -52.9M
Purchases of property, plant and equipment (EUR) -10.5M -18.9M -92.2M -29.2M -14.2M -13.9M -4.42M
Purchases of intangible assets (EUR) -382,000 -535,000 -942,000 -76,000 -81,000 -2.58M -61,000
Interest paid (cash effect) (EUR) -2.62M -4.71M -8.42M -9.21M -12.6M -20M -30.7M
Income taxes paid (cash effect) (EUR) -2.35M -2.02M -1.63M -154,000 -1.24M -1.55M -2.2M
Free cash flow (OCF - PPE - intangibles) (EUR) -5.36M 118M -16.3M -275M -217M -83.7M -57.4M
Income detail
Research and development expense (EUR) 38M 84.5M 173M 105M 59.9M 74.1M 85.3M
↳ 5y CAGR +14.3% +0.2%
Total comprehensive income (EUR) — -62M -76.1M -143M -98.3M -13.5M -115M
Comprehensive income to owners (EUR) -1.1M -62M -76.1M -143M — — —
Reported Mar 23, 2022 Mar 30, 2023 Mar 30, 2023 Mar 22, 2024 Mar 22, 2024 Mar 24, 2025 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Îlot Saint-Joseph, Bureaux Convergence, Bât. A, Bull 3 Bear 0 Clinical/regulatory

Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®

•94% of participants maintained seroresponse five years after a single vaccination

•Comparable antibody persistence observed in older (65+) and younger adults

•Data further reinforce IXCHIQ®'s differentiated profile with durable antibody persistence against an unpredictable outbreak disease

Lyon (France), November 10, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive five-year antibody persistence data for its single dose chikungunya vaccine IXCHIQ®. The results demonstrate durable antibody persistence across all age groups evaluated and are consistent with previously reported persistence results1,2,3,4. The results are in line with Valneva’s expectations for this vaccine, further supporting IXCHIQ®'s differentiated profile and its potential to provide long-term protection following a single vaccination, similarly to other live-attenuated vaccines5,6.

Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals

Lyon (France), November 9, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive results from two Phase 2 trials of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis. Valneva is evaluating the complete dataset of the Phase 2 infant and CHIM trials to determine the most appropriate path forward for the potential first-in-class vaccine candidate.

Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections annually are due to Shigella of which 62.3 million occur in children younger than five years1. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world.

Prompts

Valneva SE (ticker VLA), listed in France.

ETFs Holding Valneva SE

ETF Weight in ETF Shares Market value As of
AVSD 0.00% 6,494 $ 18.463K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
VALN Common share — US nasdaq 6.19 USD 2026-09-30
VLA canonical Common share — FR euronext 4.40 EUR 2026-01-22